Intravenous immunoglobulin in the treatment of childhood Stevens Johnson syndrome

Journal of Paediatrics and Child Health

Volumn 47, Issue 6, 2011, Pages 392-395

  Britton, Philip ^a   Deng, Lucy ^a  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; IMMUNOGLOBULIN;

DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; HUMAN; LENGTH OF STAY; NOTE; PRIORITY JOURNAL; STEVENS JOHNSON SYNDROME; SYSTEMATIC REVIEW; TOXIC EPIDERMAL NECROLYSIS;

CHILD; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; MALE; STEVENS-JOHNSON SYNDROME; TREATMENT OUTCOME;

EID: 79959855939     PISSN: 10344810     EISSN: 14401754     Source Type: Journal    
DOI: 10.1111/j.1440-1754.2011.02131.x     Document Type: Note

References (17)

1. Huff JC, Weston WL, Tonnesen MG. Erythema multiforme: a critical review of characteristics, diagnostic criteria, and causes. J. Am. Acad. Dermatol. 1983; 8: 763-75.
2. Bachot N, Roujeau JC. Intravenous immunoglobulins in the treatment of severe drug eruptions. Curr. Opin. Allergy Clin. Immunol. 2003; 3: 269-74.
3. Kuhn-Cordova I, Ramirez-Bouchan D, Gamboa-Marrufo JD. Use of intravenous immunoglobulin in toxic epidermal necrolysis and Stevens-Johnson syndrome. An. Pediatr. 2007; 67: 68-73.
4. Zipitis CS, Thalange N. Intravenous immunoglobulins for the management of Stevens-Johnson syndrome with minimal skin manifestations. Eur. J. Pediatr. 2007; 166: 585-8.
5. Viard I, Wehrli P, Bullani R et al. Inhibition of toxic epidermal necrolysis by blockade of CD35 with human intravenous immunoglobulin. Science 1998; 282: 490-3. (Pubitemid 28483679)
6. Koh MJ, Tay YK. Stevens-Johnson syndrome and toxic epidermal necrolysis in Asian children. J. Am. Acad. Dermatol. 2010; 62: 54-60.
7. Morici MV, Galen WK, Shetty AK et al. Intravenous immunoglobulin therapy for children with Stevens-Johnson syndrome. J. Rheumatol. 2000; 27: 2494-7.
8. Metry DW, Jung P, Levy ML. Use of intravenous immunoglobulin in children with Stevens-Johnson syndrome and toxic epidermal necrolysis: seven cases and review of the literature. Paediatrics 2003; 112: 1430-6. (Pubitemid 37523435)
9. Prins C, Vittorio C, Padilla RS et al. Effect of high-dose intravenous immunoglobulin therapy in Stevens - Johnson syndrome: A retrospective, multicenter study. Dermatology 2003; 207: 96-9.
10. Oxford Centre for Evidence-based Medicine - Levels of Evidence. Centre for evidence-based medicine. 2009. Available from: http://www.cebm.net/index. aspx?o=1025 [accessed 2 June 2010].
11. NHS Public Health Resource Unit. Critical Appraisal Skills Programme (CASP) - 10 questions to help you make sense of qualitative research. 2006. Available from: http://www.sph.nhs.uk/sph-files/caspappraisal-tools/ Qualitative%20Appraisal%20Tool.pdf [accessed 2 June 2010].
12. Chung WH, Hung SI, Hong HS et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004; 428: 486.
13. Kaniwa N, Saito Y, Aihara M et al. HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics 2008; 9: 1617-22.
14. Renfro L, Grant-Kels JM, Feder HM Jr, Daman LA. Controversy: are systemic steroids indicated in the treatment of erythema multiforme? Pediatr. Dermatol. 1989; 6: 43-50. (Pubitemid 19098550)
15. Rasmussen JE. Erythema multiforme in children. Response to treatment with systemic corticosteroids. Br. J. Dermatol. 1976; 95: 181-6.
16. Young PK, Ruggeri SY, Galbraith S, Drolet BA. Vesicular eczema after intravenous immunoglobulin therapy for treatment of Stevens-Johnson syndrome. Arch. Dermatol. 2006; 142: 247-8.
17. Koh MJ, Tay YK. An update on Stevens-Johnson syndrome and toxic epidermal necrolysis in children. Curr. Opin. Pediatr. 2009; 21: 505-10.